The Biotech Market Grows as Demand for New Therapeutics Increases

NEW YORK, February 6, 2017 /PRNewswire/ --

According to Global Market Insights, Inc. the biotechnology market size was valued at over USD 330.3 billion in 2015 and will exceed USD 775.2 billion with 9.9% CAGR from 2016 to 2024. A major reason for the projected growth this sector is that chronic diseases have increased the demand for innovations similar to DNA sequencing, microassays and recombinant DNA technologies to develop therapeutic solutions. Government support for R&D has helped development of products and vaccines for such chronic diseases. The report indicates that the U.S. biotechnology market size held dominant position in terms of industry revenue share followed by Europe with this trend likely to continue throughout the forecast period. Actinium Pharmaceuticals, Inc. (NYSE: ATNM), Pulmatrix Inc. (NASDAQ: PULM), Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), Amarin Corporation (NASDAQ: AMRN), Amicus Therapeutics Inc. (NASDAQ: FOLD)

Cancer continues to be a major area of concern. The World Health Organization indicates that the increasing use of tobacco and alcohol consumption around the world is expected to increase the number of new cancer cases by about 70% over the next two decades. Cancer is still one of leading causes of death worldwide and demand for cancer treatments keeps growing. The need for improving cancer therapies is constantly pushing biotechnology companies to invest in innovation and clinical trials to find new cancer therapeutics. According to a recent report from Mordor Intelligence, the global Cancer therapy market is estimated to grow at 17.6% CAGR to reach $52.2 billion by 2021. 

Actinium Pharmaceuticals, Inc. (NYSE: ATNM), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, recently announced that Dr. Mark Berger has been appointed Chief Medical Officer effective today. Dr. Berger joins Actinium with significant drug development expertise that includes the planning and execution of clinical trials that led to the FDA approval of Mylotarg for acute myeloid leukemia (AML) while at Wyeth Research (now Pfizer), and Tykerb for breast cancer while at GlaxoSmithKline. He also has experience in patient care and lab-based cancer research. Dr. Berger will report to Sandesh Seth, Actinium's Executive Chairman.

"Dr. Berger has a stellar track record in hematology/oncology research and drug development that makes him perfectly suited for the position of Chief Medical Officer at Actinium," said Sandesh Seth. "Dr. Berger led the development of Mylotarg, which like Actimab-A, is a CD33 targeting agent. Mylotarg remains the only drug approved in AML in the last several decades, and Dr. Berger was integral to Mylotarg's approval as highlighted by his presentation to ODAC. This along with Mark's many other accomplishments in drug development, medical training and research experience gives us great confidence in his ability to build a robust clinical development organization to execute on the clinical development of Iomab-B, Actimab-A and our future clinical programs." 

"I am impressed with the potential for Actinium's radioimmunotherapy technology," Dr. Berger said. "The data to date on Iomab-B and Actimab-A are very compelling and suggest that radioimmunotherapy has the potential to be safe and effective particularly in difficult clinical indications such as bone marrow transplant conditioning in patients with AML, or in the treatment of older patients with AML. I am excited to join the Actinium team and look forward to executing on a clinical development strategy that will bring these therapies to approval."

Clinical stage biopharmaceutical company, Pulmatrix Inc. (NASDAQ: PULM) is currently advancing a pipeline of product candidates to treat serious chronic obstructive pulmonary diseases and asthma. The company's anti-fungal product candidate for cystic fibrosis is the most advanced program in its pipeline of treatments for rare, orphan disease. Its PUR1500 is an iSPERSE (inhaled small particles easily respirable and emitted) formulation that combines a kinase inhibitor with established anti-angiogenesis activity for the treatment of idiopathic pulmonary fibrosis and its PUR0200 is also an iSPERSE formulation that's a long-acting muscarinic antagonist bronchodilator.

Biopharmaceutical company focused on the global immunology market, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has selected Worldwide Clinical Trials as its Clinical Research Organization for the AURORA Phase 3 study of volcosporin for the treatment of active lupus nephritis. Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous. "Selecting a CRO for AURORA is a key milestone for Aurinia following our successful end-of-Phase 2 meeting with the U.S. Food & Drug Administration Division of Pulmonary, Allergy and Rheumatology Products. We are thrilled to partner with Worldwide to support the AURORA Phase 3 clinical trial," said Charles Rowland, Chief Executive Officer of Aurinia. "We are rapidly moving forward with our plans to bring this important therapy to market for patients living with this devastating disease, and Worldwide's deep expertise and capabilities in managing pivotal trials will be a tremendous asset to us. We are on track to commence the AURORA trial in the second quarter of 2017, and we expect the results from this study will support a New Drug Application submission to the FDA."

Amarin Corporation (NASDAQ: AMRN) is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA approved product that is used together with a low-fat and low-cholesterol diet to reduce triglycerides in adults with severely high triglycerides.

Amicus Therapeutics Inc. (NASDAQ: FOLD) is a global biotechnology company of advanced therapies that treats a range of devastating rare and orphan diseases. The company's lead product candidate, migalastat, is a personalized medicine in late-stage development to treat individuals with Fabry disease on the basis of their genetic diagnosis. SD-101, a product candidate in late-stage development, is a potential first-to-market therapy for the rare genetic connective tissue disorder Epidermolysis Bullosa. The company is leveraging its biologics and Chaperone-Advanced Replacement Therapy platform technologies to develop novel enzyme replacement therapy products for Fabry disease, Pompe disease, and other Lysosomal Storage Disorders. Its leading biologics program is ATB200/AT2221, a uniquely engineered Pompe disease ERT that will be administered in combination with a pharmacological chaperone.

Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only regurgitates financial or corporate news through our unique financial newswire and media platform. FinancialBuzz.com has been compensated a total of twelve thousand dollars for financial news dissemination and pr services by a third party non affiliate for actinium pharmaceuticals inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com

For further information:
Media Contact:
info@financialbuzz.com
+1-877-601-1879

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com